Compare GSK plc (GSK) vs Hafnia Limited Common Shares (HAFN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Hafnia Limited Common Shares — how do they compare? GSK plc trades at $48.45 (market cap $96.45B), while Hafnia Limited Common Shares trades at $10.13 (market cap $5.67B). The key difference: GSK plc is far larger — about 17× Hafnia Limited Common Shares's market cap, and Hafnia Limited Common Shares pays the higher dividend (10.44%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Hafnia Limited Common Shares for 0 Days on average.
| GSK | HAFN | |
|---|---|---|
Market Cap | $96.45B | $5.67B |
Volume | 7,087,457 | 3,240,007 |
Sector | Health | Industrials |
52-Week High | $61.18 | $10.92 |
52-Week Low | $43.24 | $5.21 |
Typical Hold Time | 93 Days | 0 Days |
Enterprise Value | $116.51B | $6.29B |
Dividend Yield | 3.79% | 10.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.27, down 1.39% today, with a bearish technical signal from moving averages. The company shows strong profitability with 72.73% gross margins and 14.52% net income margin, supported by three consecutive quarterly earnings beats. Recent developments include a $750M cancer therapy acquisition and strategic focus on oncology growth targeting £40B in sales. Cash flow trends show consistent operational strength with $7.7B from operations in 2025.
GSK presents a mixed outlook with strong fundamentals offset by technical weakness. The stock offers value with a 14.84 P/E ratio and dividend yield, but faces headwinds from HIV patent expirations and bearish technical indicators. Analyst consensus leans cautious with 55% hold ratings, suggesting patience may be warranted despite the company's solid operational performance.
HAFN trades at $10.85, down 0.64% on the day, with a neutral technical signal. The company shows strong fundamentals, with a P/E of 8.35 and net income margin of 24.7%. Recent earnings have consistently beaten expectations, and analysts maintain a 100% buy rating. Key developments include a CEO transition and strategic acquisitions.
Outlook is positive due to robust profitability and growth projections, with 2026 revenue expected to reach $2.7B. Risks include market volatility and execution of new strategies. The stock presents a value opportunity with upside potential, supported by strong cash flow and institutional confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Hafnia Limited Common Shares
Hafnia Limited owns and operates a fleet of product and chemical tankers that transport refined oil products, vegetable oils, and chemicals for oil and chemical companies worldwide, across the Long Range, Medium Range, and Handy tanker segments, headquartered in Singapore.
Read more on HAFN →
